Genetic Testing Market – By Product & Service (Kit, Reagent, Software, Service), Test Type (Predictive, Carrier, Diagnostics, Prenatal, Newborn), Application (Cancer, Paternity, Forensic), Technique (PCR, Sequencing), End-use, Global Forecast (2024 ­ 2032)

Genetic Testing Market Size

Genetic Testing Market size was valued at USD 19.4 billion in 2023 growing at a CAGR of 11.7% from 2024 to 2032. One of the primary drivers is the increasing prevalence of genetic diseases.
 

For instance, as per the WHO, genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, account for up to 30% of paediatric hospital admissions and cause about 50% of childhood deaths in industrialized countries. Thus, the rising incidence of genetic and hereditary diseases has created a greater need for early and accurate diagnosis, thereby fuelling the market growth.
 

Further, increasing awareness and acceptance of personalized medicine and precision healthcare approaches have significantly expanded the demand for genetic testing services. Advancements in genomic technologies, such as next-generation sequencing (NGS), have made genetic testing more accessible, affordable, and comprehensive, driving adoption across clinical diagnostics and research applications. Additionally, supportive government initiatives and investments in genetic research, coupled with expanding applications in oncology, pharmacogenomics, and prenatal screening, are enhancing market expansion globally.
 

Genetic testing is a medical test that identifies changes in chromosomes, genes, or proteins to detect genetic disorders or conditions. It can provide information about a person's genetic makeup and their risk for developing or passing on certain genetic conditions. Several genetic tests can be performed using various techniques such as polymerase chain reaction, DNA sequencing, cytogenetic testing, microarrays, and gene expression profiling.
 

Genetic Testing Market Trends

• Technological advancements in genetic testing technologies, such as next-generation sequencing (NGS), have significantly reduced the cost and time required for genetic testing. This makes it more accessible and practical for a wide range of applications.
   
• Additionally, the introduction of next generation sequencing genetic tests is anticipated to propel the growth of market.
   
• For instance, in April 2024, Revvity launched a next-generation sequencing-based panel and workflow for newborn screening that will complement existing screening programs, which largely employ biochemical testing.
   
• Moreover, the use of technologically advanced genetic testing diagnostic tools significantly expands the range of conditions that can be tested and broadens horizon in research areas, further boosting the market growth.
   

Genetic Testing Market Analysis

Based on the product & service, the global market is classified into kits & reagents, and software & services. The kits & reagents segment dominated the market with revenue of USD 12.3 billion in 2023.
 

• The development and adoption of NGS technologies have significantly increased the efficiency, speed, and cost-effectiveness of genetic testing. This has led to a higher demand for advanced kits and reagents that support NGS processes.
   
• Moreover, growing research activities in genomics and personalized medicine are driving the demand for high-quality kits and reagents. Researchers require reliable and precise tools to conduct experiments and validate findings, thereby contributing to the growth of the market.
   
• Furthermore, the rise in direct-to-consumer genetic testing services has significantly increased the demand for kits and reagents, thereby propelling the segmental growth.
   

Based on the test type, the global genetic testing market is classified into predictive testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomics testing, nutrigenomics, and other test types. The diagnostic testing segment dominated the market with market share of 51.1% in 2023.
 

• Demonstrated clinical utility of genetic testing in diagnosing rare and complex genetic disorders, is one of the major factors that is anticipated to drive the diagnostic testing segment.
   
• Further, increasing awareness among patients and healthcare providers about the benefits of early disease detection and personalized treatment options has fueled the demand for diagnostic genetic testing.
   
• Additionally, advancements in technology, such as next-generation sequencing (NGS) and PCR-based assays, have enhanced the accuracy, speed, and cost-efficiency of genetic diagnostics, further boosting market growth.
   

Based on application, the genetic testing market is classified into cancer treatment, tissue typing for transplantation, forensic identity testing, ancestry testing, paternity testing, and other applications. The cancer treatment segment is expected to reach USD 16.8 billion by the end of 2032.
 

• Advances in genetic testing technologies have enhanced the cancer diagnostic ability to detect genetic predispositions at earlier stages of the cancer. Early detection can lead to earlier intervention and potentially better patient outcomes.
   
• Furthermore, genetic testing data contributes to the development of new cancer treatments and therapies through clinical trials. This fosters innovation in cancer treatment strategies and expands the range of options available to patients, thereby augmenting the market growth.
   

Based on technique, the global genetic testing market is classified into polymerase chain reaction, DNA sequencing, cytogenetic testing, microarrays, and gene expression profiling. The DNA sequencing segment dominated the market with market share of 30.1% in 2023.
 

• Reduction in the cost of sequencing per base pair has made DNA sequencing more accessible and affordable, thereby increasing adoption rates among healthcare providers and researchers.
   
• Moreover, active research and development efforts in genomics and genetics have expanded the understanding of genetic variations, driving the demand for sequencing services in both research and clinical settings.
   
• Furthermore, increasing consumer awareness and demand for direct-to-consumer genetic testing services, which often rely on DNA sequencing, are contributing to the segmental growth.
   

Based on end-use, the genetic testing market is classified into hospitals & clinics, diagnostic laboratories, forensic laboratories, and other end-users. The hospitals & clinics segment is expected to exhibit 12% CAGR between 2024 - 2032.
 

• Hospitals and clinics are increasingly adopting genetic testing to personalize treatment plans based on a patient's genetic profile. This trend is driven by the growing understanding of genetic variations influencing disease susceptibility and drug response.
   
• Moreover, collaborations between genetic testing companies and healthcare providers facilitate the integration of testing services into existing hospital and clinic workflows, making testing more accessible, thereby supplementing the segmental growth.
   

In 2023, North America secured a substantial market share of 53.1% in the global genetic testing market and is expected to dominate throughout the forecast period.
 

• The region faces rising incidences of genetic disorders such as cystic fibrosis, Huntington's disease, and certain types of cancer. This fuels demand for genetic testing for early detection, disease management, and personalized treatment options.
   
• Moreover, North America leads in the adoption of personalized medicine approaches, which rely heavily on genetic testing to tailor treatments based on an individual's genetic profile. This trend boosts market expansion as healthcare providers integrate genetic testing into routine clinical practice.
   
• Furthermore, well-established regulatory frameworks in countries like the U.S. and Canada provide a clear pathway for approval and adoption of new genetic tests. This fosters innovation and investment in the genetic testing sector, contributing to market growth.  
   

The genetic testing market in the U.S. is expected to exhibit 11.6% CAGR between 2024 - 2032.
 

• The overall increase in healthcare expenditure in the U.S., coupled with insurance coverage for genetic testing in many cases, makes testing more accessible to a larger population, thereby contributing the market growth.
   
• In addition, strong academic and institutional research collaborations, along with government initiatives like the Precision Medicine Initiative, foster development, and adoption of genetic testing technologies in the country, thus boosting the market growth.
   

Germany to experience the highest growth rate in the Europe market.
 

• Germany has a strong regulatory framework ensuring quality and safety standards for genetic tests. Supportive government policies and funding for research and development in genetic testing technologies encourage market growth.
   
• Moreover, Germany is known for its advancements in biotechnology and healthcare technology. Innovations in genetic testing methodologies, including next-generation sequencing (NGS) and PCR-based tests, contribute to market expansion, fostering market growth.
   

The Asia Pacific genetic testing treatment market is expected to grow with a significant CAGR of 12.1% during the forecast period.
 

• Rapid advancements in genomic technologies and decreasing costs of genetic sequencing are making genetic testing more accessible across the region.
   
• Moreover, higher prevalence of genetic disorders in some populations within Asia-Pacific countries is propelling the demand for genetic testing services, thereby contributing to the growth of the market in this region.
   
• Furthermore, there is a greater awareness of the possibility of detecting genetic disorders in fetuses through prenatal testing, leading to more expectant parents opting for these tests, thereby contributing to the growth of the market in this region.
   

Genetic Testing Market Share

The competitive landscape of the genetic testing industry is characterized by intense rivalry among key players striving to innovate and expand their market presence. Leading companies such as Abbott Laboratories, Illumina Inc., and Qiagen N.V. dominate the market with their extensive product portfolios and robust R&D investments. Additionally, mergers, acquisitions, and strategic partnerships are common strategies employed to broaden market reach and access new technological capabilities.
 

Genetic Testing Market Companies

Prominent players operating in the genetic testing industry are as mentioned below:

• 23 and ME, Inc.
• Abbott Laboratories
• Ambry genetics
• Ancestry DNA
• bioMerieux SA
• BGI Genomics
• Eurofins Scientific
• Illumina, Inc.
• Invitae Corporation
• Luminex Corporation
• Myriad Genetics, Inc.
• Natera, Inc.
• QIAGEN N.V.
• Quest Diagnostics
• Siemens Healthineers AG
   

Genetic Testing Industry News:

• In February 2024, Sysmex Corporation and Hitachi High-Tech Corporation announced that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers). This strategy is expected to enhance the company’s outreach to untapped economies.
   
• In July 2023, Quest Diagnostics announced the launch of its first consumer-initiated genetic test, called Genetic Insights. The new offering helps people understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counselling. This helped the company expand its product offerings.
   

The genetic testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Products & Services

• Kits & reagents
• Software & services

Market, By Test Type

• Predictive testing
• Carrier testing
• Prenatal and newborn testing
• Diagnostic testing
• Pharmacogenomic testing
• Nutrigenomics
• Other test types

Market, By Application

• Cancer treatment
• Tissue typing for transplantation
• Forensic identity testing
• Ancestry testing
• Paternity testing
• Other applications

Market, By Techniques

• Polymerase chain reaction
• DNA sequencing
  • Sanger sequencing
  • Next generation sequencing
• Cytogenetic testing
  • Chromosome analysis (karyotyping)
  • Fluorescence in situ hybridization (FISH)
• Microarrays
• Gene expression profiling

Market, By End-use

• Hospitals & clinics
• Diagnostic laboratories
• Forensic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa